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ABSTRACT
The purpose of this study was to determine the longitudinal association between menopausal vasomotor symptoms (VMS) and urinary
N-telopeptide level (NTX) according to menopausal stage. We analyzed data from 2283 participants of the Study of Women’s Health
Across the Nation, a longitudinal community-based cohort study of women aged 42 to 52 years at baseline. At baseline and annually
through follow-up visit 8, participants provided questionnaire data, urine samples, serum samples, and anthropometric measurements.
Usingmultivariable repeated-measuresmixedmodels,weexaminedassociationsbetweenannuallyassessedVMSfrequencyandannual
NTX measurements. Our results show that mean adjusted NTX was 1.94 nM of bone collagen equivalents (BCE)/mM of creatinine higher
among early perimenopausal women with any VMS than among early perimenopausal women with no VMS (p<.0001). Mean adjusted
NTX was 2.44 nM BCE/mM of creatinine higher among late perimenopausal women with any VMS than among late perimenopausal
women with no VMS (p¼.03). Among premenopausal women, VMS frequency was not significantly associated with NTX level. When
NTX values among women with frequent VMS ( 6 days in past 2 weeks) were expressed as percentages of NTX values among women
without frequent VMS, the differences were 3% for premenopausal women, 9% for early perimenopausal women, 7% for late
perimenopausal women, and 4% for postmenopausal women. Adjustment for serum follicle-stimulating hormone (FSH) level greatly
reduced the magnitudes of associations between VMS and NTX level. We conclude that among early perimenopausal and late
perimenopausalwomen,thosewithVMShadhigherboneturnoverthanthosewithoutVMS.Priortothefinalmenstrualperiod,VMSmay
be a marker for risk of adverse bone health.  2011 American Society for Bone and Mineral Research.
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Introduction
V
asomotor symptoms (hot flashes and/or night sweats; VMS)
occur in approximately 50% to 70% of peri- and post-
menopausal women.
(1–7) VMS prevalence increases sharply in
the 2 years before the final menstrual period.
(6,7) Approximately
35% to 50% of pre- and perimenopausal women report having
VMS.
(1–5,7) Thus VMS are not uncommon prior to the final
menstrual period.
In studies of midlife women, we and others have found that
mean bone mineral density (BMD) is lower among women with
VMS than among women without VMS.
(8–11) One possible reason
for this inverse association between VMS and BMD is that VMS
may be associated with increased bone turnover, in turn, leading
to decreased BMD.
An association of VMS with increased bone turnover in midlife
women might be expected on the basis of prior studies
linking cortisol and sympathetic nervous system activation to
both hot flashes and BMD. Serum cortisol and serum epin-
ephrine may increase in association with hot flashes,
(12–14)
and systolic blood pressure may be higher among women with
hot flashes than among women without hot flashes.
(15)
Also, brain norepinephrine metabolites increase during hot
flashes.
(16)
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840Sustained or frequent elevations in serum cortisol and/or
serum epinephrine owing to their relations with hot flashes may
have adverse effects on bone health. For example, medication-
induced blockage of the sympathetic nervous system (by beta
blockers) has favorable effects on trabecular microarchitecture
andcorticalwidthofthefemur,aswellashipandlumbarBMD,in
postmenopausal women.
(17) In addition, the majority of case-
control studies of BMD that have included women have reported
higher BMD among users compared with nonusers, of beta
blockers.
(17–19) Beta-blocker administration increases BMD in
mice.
(19) Conversely, administration of beta-agonist medications
has deleterious effects on trabecular bone architecture and
accelerates bone resorption in rats
(20) and decreases BMD in
mice.
(21) An additional theory for the association between VMS
and BMD could be interindividual differentials in estrogen
‘‘sensitivity’’ at the menopause transition; a higher sensitivity to
the reduction in estrogen levels may underlie certain women
having both frequent VMS and greater bone loss.
An association of VMS with increased bone turnover [urinary
N-telopeptidelevel(NTX)] wasfound inonecross-sectional study
of infertile premenopausal women,
(22) but the association has
not been studied prospectively over the menopause transition.
Given the substantial prevalence of VMS even among women
who have not yet had their final menstrual period, an association
of VMS with adverse indicators of bone health could affect many
women. We hypothesized that the presence of VMS would be
related to higher levels of urinary N-telopeptide among midlife
women even prior to the postmenopausal stage. To address this
hypothesis, we used longitudinal data collected from baseline
and eight annual follow-up visits in the Study of Women’s Health
Across the Nation (SWAN), a large, prospective, community-
based study of the menopausal transition.
Methods
The Study of Women’s Health Across the Nation (SWAN)
and the SWAN bone study
To determine the association between BMD and urinary NTX
level, we used data from baseline through annual follow-up visit
8 from SWAN, a multisite, longitudinal, community-based cohort
study of 3302 women. At baseline, SWAN participants were aged
42 to 52 years and premenopausal or early perimenopausal with
an intact uterus and one or more ovaries, were not pregnant or
lactating, and were not using exogenous reproductive hor-
mones.
(23) (Please see below for a definitions of menopausal
stages.) Each of the seven study sites enrolled white women in
addition to women of one other site-specific, self-identified
racial/ethnic group: African-American women (Boston, Detroit
area, Chicago, and Pittsburgh), Japanese women (Los Angeles),
Hispanic women (New Jersey), and Chinese women (Oakland,
CA). SWAN participants completed questionnaires, provided a
morning urine sample, and underwent fasting blood sampling
annually. If annual phlebotomy could not be performed in the
early follicular phase (days 2 to 5) of the menstrual cycle within
60 days of the anniversary visit date (usually because of irregular
menstrual cycles), blood was obtained without respect to
menstrual bleeding.
(24)
For the SWAN bone substudy, five of the SWAN sites (Boston,
Pittsburgh, Detoit, Oakland, and Los Angeles, n¼2413 at
baseline) measured BMD at baseline and annually.
(25,26) These
sites also collected non-first-voided urine samples (before
0900hours) between menstrual cycle days 2 and 5 for assay
of NTX. Serum and urine samples were frozen within 10hours of
collection and stored at  20 or  808C for 1 to 60 days at local
sites until analysis at a centralized laboratory (Medical Research
Laboratories, Highland Heights, KY, USA).
All protocols were approved by the institutional review board
at each of the SWAN sites. All participants provided signed,
written informed consent.
Assessment of vasomotor symptoms (VMS)
At baseline and at each annual follow-up visit, women
completed a questionnaire that included a symptom checklist.
The symptom checklist was worded as follows: ‘‘Below is a list of
common problems which affect us from time to time in our daily
lives. Thinking back over the past two weeks, please circle the
number corresponding to how often you experienced any of the
following.’’ Participants rated the frequency of hot flashes and
the frequencyofnight sweats inthe past 2weeks usingresponse
choicesofnever,1to5days,6to8days, 9to13days, ordaily. For
each visit, we classified women who had hot flashes or night
sweats or both hot flashes and night sweats as having VMS. For
this study, we classified VMS as frequent if they occurred for 6 or
more days in the past 2 weeks and not frequent if they occurred
for fewer than 6 days (or not at all) in the past 2 weeks.
Other questionnaire-based and anthropometric measures
Atbaseline andateachannual follow-upvisit,SWANparticipants
completed standardized questionnaires and underwent mea-
surement of height and weight for calculation of body mass
index (BMI, weight in kilograms divided by the square of height
in meters). We collected information regarding age, race/
ethnicity, reproductive and menstrual history, medication use,
smoking,physicalactivity,dietary intake,and alcoholintake from
baseline and annual questionnaires.
Menopausal status, based on self-reported menstrual cycle
characteristics recalled over the past year, were premenopausal
(menstruation in the past 3 months with no change in menstrual
regularity in the past year), early perimenopausal (menstruation
in the past 3 months with decreased regularity in the past year),
late perimenopausal (no menses for 3 to 11 months), and
postmenopausal (no menses for the past 12 months).
At baseline and at annual follow-up visit 5, using a modified
1995 Block Food Frequency Questionnaire, we assessed usual
alcohol intake in kilocalories per day.
(27–29) Annual question-
naires assessed the usual frequency of supplement intakes of
calcium and vitamin D since the last visit using response choices
of ‘‘Don’t take any,’’ ‘‘1 to 3 days per week,’’ ‘‘4 to 6 days per
week,’’ or ‘‘every day.’’
SWAN used an adaptation of the Kaiser Physical Activity
Survey to assess physical activity at baseline, annual follow-up
visit 3, and annual follow-up visit 6.
(30) Using Likert-scale
responses from 1 to 5, the questionnaire asked about several
domains of physical activity: household/caregiving, sports/
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hours of television viewing reverse-scored). The physical activity
score was the sum of the active living, sports, and household
caregiving scores (range 4 to 20).
Laboratory assay methodology
At baseline and annually through follow-up visit 8, urinary NTX
level was measured using an automated competitive immu-
noassay (Vitros ICi, Rochester, NY, USA). NTX was expressed as
nanomolesofbonecollagenequivalentsperliterpermillimoleof
creatinine per liter (nM BCE/mM creatinine). The lower limit of
detection was 10 nM BCE, and intra- and interassay coefficients
of variation were 2.75% and 4.8%, respectively, over the assay
range. Creatinine was measured on the Cobas Mira (Horiba ABX,
Montpellier, France) based on the Jaffe reaction. The lower limit
of detection was 0.014mM, and the intra- and interassay
coefficients of variation were 0.62% and 4.12%, respectively,
across the assay range.
To measure serum estradiol level, SWAN used a semiauto-
mated competitive ACS:180 immunoassay with manual steps
and an off-line incubation. Inter- and intraassay coefficients of
variation averaged 10.6% and 6.4%, respectively, at an estradiol
level of 50pg/mL.
(24) Serum follicle-stimulating hormone (FSH)
was measured with a two-site chemiluminometric immunoassay
using constant amounts of two monoclonal antibodies, each of
which was directed at different regions on the b subunit. One
antibody was coupled with paramagnetic particles; the other
antibody was labeled with dimethylaminoethanol.
(24) Inter- and
intraassay coefficients of variation were 12.0% and 6.0%,
respectively, at an FSH level of 15 IU/L.
(24)
Analytic sample
This analysis is based on data from SWAN bone study parti-
cipants for whom we had at least one concurrent measurement
of NTX and VMS (n¼2336 participants at baseline). For this
study, we censored data from women at the time they reported
having a hysterectomy or bilateral oophorectomy, becoming
pregnant, or breast-feeding. We also excluded data from women
taking medications that might influence osteoporosis (eg,
corticosteroid pills, epilepsy medications, alendronate, risedro-
nate, raloxifene, calcitonin, teriparatide, ibandronate, etidronate,
fluoride, chemotherapy, tamoxifen, or exogenous hormone
therapy) by censoring their data starting at the time they first
reported taking the exclusionary medications. For example, if a
participant first reported using an exclusionary medication at
annual follow-up visit 6, information for that participant was
excluded for visit 6 and all subsequent follow-up visits. These
criteria resulted in an analytic sample of 2283 participants at
baseline and 686 participants at follow-up 8.
Statistical analysis
We used repeated-measures mixed models with an autore-
gressive AR1 model to account for within-woman correlation.
(31)
We examined the associations between VMS in each of the four
menopausal stage categories (the primary predictors) and
repeated annual measurement values of urinary NTX (outcome).
On the basis of prior studies,
(32) we included age (continuous),
cigarette smoking (current versus not current), BMI (continuous,
kg/m
2), race/ethnicity (African-American, Caucasian, Chinese, or
Japanese), calcium and vitamin D supplement intake (none, 1 to
3 days per week, 4 to 6 days per week, or daily), physical activity
score, alcohol intake (kcal/day, log-transformed), and study site
as covariates in all multivariable models. For physical activity and
alcohol intake, we used the most recent values. All covariates
were treated as time-varying covariates except for race/ethnicity
and study site.
We conducted analyses using multiple definitions of the VMS
outcome to assess robustness and consistency of results. Three
sets of models were run, the first setwith VMScategorized as any
versus none, the second set with VMS categorized as frequent
versusnotfrequent( 6daysversus<6daysinthepast2weeks),
and the third set with VMS frequency (the higher value of
frequency of hot flashes or frequency of night sweats in the past
2 weeks) treated as an ordinal variable ranging from 1 to 5
(1¼never; 2¼1 to 5 days; 3¼6 to 8 days; 4¼9 to 13 days;
5¼daily).
Based on prior analyses of associations between VMS and
BMD, we had an apriori hypothesis that associations of VMSwith
NTX would vary by menopausal stage.
(33) Thus we included a
VMS menopausal stage interaction term in the repeated-
measures mixed models.
We performed secondary analyses in which we added serum
estradiol level and serum FSH level (individually and then
simultaneously) as time-varying covariates to the repeated-
measures models described earlier. Inthese models, we included
an indicator variable representing whether serum for FSH and
estradiol levels was drawn in the early follicular phase of the
menstrual cycle (days 2 to 5 versus not days 2 to 5 or unknown).
We additionally analyzed associations between VMS and NTX in
two separate strata according to whether levels were drawn in
the early follicular phase or not.
Statistical analyses were performed using SAS 9.2 (SAS
Institute, Inc., Cary, NC, USA).
Results
Participant characteristics
In our final analytic sample, the number of participants was 2283
at baseline and 686 at follow-up 8 (Table 1). At baseline, 54%
of participants were premenopausal, and 46% of participants
were early perimenopausal (Table 2). Mean age at baseline was
45.8 years, and mean BMI was 28.0kg/m
2. Forty-nine percent of
the analytic sample was white. At baseline, 31.5% of pre-
menopausal participants and 47.2% of early perimenopausal
participants reported having any VMS (Table 3). At baseline,
frequent VMS ( 6 days in the past 2 weeks) were reported by
7.6% of premenopausal women and 14.7% of early perimeno-
pausal women. By the eighth annual follow-up visit, 44.4% of
premenopausal participants, 47.3% of early perimenopausal
participants, 72.6% of late perimenopausal participants, and
62.4% of postmenopausal participants reported having any VMS.
By the eighth annual follow-up visit, frequent VMS ( 6 days in
the past 2 weeks) were reported by 11.1% of premenopausal
women, 15.8% of early perimenopausal women, 40.6% of
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Association of VMS and NTX according to menopausal
stage
A pattern of increasing mean unadjusted urinary NTX level was
observed with advancing menopausal stages (Table 4). NTX
values were statistically significantly higher among women with
VMS (any versus none) than among women who did not have
VMS at every menopausal stage except at the premenopausal
stage. When NTX values among women with frequent VMS were
expressed as percentages of NTX values among women without
frequent VMS, the differences were 3% for premenopausal
women, 9% for early perimenopausal women, 7% for late
perimenopausal women, and 4% for postmenopausal women
(calculated from values in Table 4; data not shown).
The association of VMS with mean urinary NTX varied by
menopausal stage (pinteraction¼.07 when VMS was expressed as
any versus none; pinteraction¼.01 when VMS was expressed as
frequent versus not frequent).
NTX levels were similar among women reporting never having
hot flashes compared with women having hot flashes 1 to 5 days
in the past 2 weeks (ANOVA p>.05). NTX levels likewise were
similaramong women reporting 6to 8days, 9to 13 days, or daily
hot flashes in the past 2 weeks (ANOVA p>.05) but different
from those among women with no hot flashes or 1 to 5 days of
hot flashes in the past 2 weeks (p<.05). Thus we do not show
results of analyses in which VMS frequency was treated as an
ordinal variable for subsequent adjusted analyses.
During the early and late perimenopause, the presence of any
VMS was associated with higher urinary NTX values after
adjustment for age, current smoking, race/ethnicity, calcium
and vitamin D supplement use, physical activity level, alcohol
intake, and study site (Table 5). Compared with women in the
same menopausal transition stage without VMS, urinary NTX
values were 1.94 nM BCE/mM of creatinine higher in early
perimenopausal women (p<.0001) and 2.44 nM BCE/mM of
creatinine higher in late perimenopausal women (p¼.03) with
any VMS.
Compared with women in the same menopausal transition
stage without frequent VMS, urinary NTX values were 3.08 nM
BCE/mM of creatinine higher in early perimenopausal women
(p<.0001), 3.63 nM BCE/mM of creatinine (p<.001) higher in
late perimenopausal women, and 1.91 nM BCE/mM of creatinine
higher in postmenopausal women (p¼.02) with VMS occurring
frequently ( 6 days in past 2 weeks). Neither the presence nor
the frequency of VMS was significantly associated with NTX level
among premenopausal women. When VMS frequency was
treated as an ordinal variable ranging 1 to 5 (1¼none; 2¼1t o
5 days; 3¼6 to 8 days; 4¼9 to 13 days; 5¼daily in the past
2 weeks), the pattern and statistical significance of associations
were similar to the results of the previous models (data not
shown).
Secondary analyses adjusted for serum estradiol and FSH
levels
Addition of FSH level to the multivariable repeated-measures
regression models markedly decreased the magnitude ofbut did
not completely eliminate associations between VMS and NTX
level, whereas adjustment for serum estradiol level had a lesser
impactonthemagnitudesofassociationsbetweenVMSandNTX
level (Table 5). Simultaneous adjustment for estradiol and FSH
produced results that were virtually identical to adjustment for
FSH level alone.
When we repeated mixed-effects regression models among
women whose FSH and estradiol levels were not drawn during
the early follicular phase (53% of estradiol and FSH values),
the magnitudes of associations between VMS and NTX were
more pronounced but showed a similar pattern of statistical
significance compared with the analytic sample as a whole
(data not shown). In contrast, among women whose estradiol
and FSH levels were drawn in the early follicular phase, no
statistically significant associations were observed between VMS
and NTX.
Table 1. Numbers of Participants With Available Urinary N-Telopeptide (NTX) Measurement According to Year of Follow-up
Visit number
a
0¼baseline 1 2 3 45678
Total no. of participants 3302 2881 2746 2710 2679 2577 2448 2368 2279
No. of participants for whom data were available
regarding NTX, VMS,
b and menopausal stage
2336 2043 1944 1830 1728 1610 1707 1663 1061
No. of participants after further censoring of
women with hysterectomy, bilateral
oophorectomy, pregnancy, breast-feeding,
hormone therapy use, use of medication known
to influence bone density, and missed visits
c
2283 1760 1521 1330 1199 1110 1147 1099 686
aVisit number 0 denotes baseline visit.
bVMS¼vasomotor symptoms.
cMedication known to influence bone density includes self-reported use of corticosteroid pills, medications for epilepsy, tamoxifen, chemotherapy, or
medications used to prevent or treat osteoporosis. Women were censored at the first visit at which they reporting taking any of these medications.
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a
Characteristic
Visit number
Baseline (n¼2283),
mean (SD)
Visit 5 (n¼1110),
mean (SD)
Visit 8 (n¼686),
mean (SD)
Body mass index (kg/m
2) 28.0 (7.5) 28.0 (7.1) 28.2 (6.8)
Physical activity score
b 7.8 (1.8) 7.7 (1.8) 7.8 (1.8)
Weight 74.2 (21.3) 73.6 (20.0) 74.1 (19.4)
Alcohol, kcal/day 42.7 (96.1) 39.8 (97.1) 40.9 (86.3)
Age, years 45.8 (2.7) 50.9 (2.7) 53.5 (2.5)
Urinary NTX, nM BCE/mM of creatinine 34.4 (16.0) 37.6 (19.4) 43.5 (19.8)
n (percent) n (percent) n (percent)
Smoking, current 370 (16%) 138 (12%) 62 (9%)
Body mass index
Underweight<19kg/m
2 82 (4%) 37 (3%) 18 (3%)
Normal weight 19–24.9kg/m
2 929 (41%) 421 (38%) 237 (35%)
Overweight 25–29.9kg/m
2 531 (24%) 299 (27%) 194 (28%)
Obese 30kg/m
2 714 (32%) 352 (32%) 236 (34%)
Ethnicity
African-American 647 (29%) 269 (25%) 159 (24%)
Caucasian 1127 (49%) 497 (46%) 328 (49%)
Chinese 243 (11%) 149 (14%) 84 (13%)
Japanese 266 (12%) 174 (16%) 98 (15%)
Menopausal stage
Premenopausal 1230 (54%) 71 (6%) 18 (3%)
Early perimenopausal 1053 (46%) 491 (44%) 184 (27%)
Late perimenopausal 0 155 (14%) 106 (15%)
Postmenopausal 0 393 (35%) 378 (55%)
Vitamin D
Don’t take any 1959 (96%) 1018 (92%) 630 (92%)
1–3 days/week 23 (1%) 16 (1%) 14 (2%)
4–6 days/week 10 (1%) 15 (1%) 12 (2%)
Every day 39 (2%) 56 (5%) 30 (4%)
Calcium supplement use
Don’t take any 1503 (74%) 712 (65%) 469 (68%)
1–3 days/week 136 (7%) 98 (9%) 50 (7%)
4–6 days/week 94 (5%) 69 (6%) 38 (6%)
Every day 297 (15%) 225 (20%) 129 (19%)
aInformation regarding these participant characteristics was obtained annually from baseline to annual follow-up visit 8, except for alcohol intake
(assessed at baseline and annual visit 5) and physical activity (assessed at baseline, annual visit 3, and annual visit 6). The values displayed for physical
activity and for alcohol intake are those from the most recent prior assessment.
bSum of household/caregiving index, activity living index, and sports index, each scored between 1 and 5, summary physical activity score possible
range 3 to 15.
Table 3. Menopausal Stage and VMS Reporting at Baseline and at Annual Follow-up Visits 5 and 8
a
Visit number
Baseline 5 8
No
VMS
VMS
1–5 days
VMS
6þ days
No
VMS
VMS
1–5 days
VMS
6þ days
No
VMS
VMS
1–5 days
VMS
6þ days
Premenopausal 842 (68.5%) 294 (23.9%) 94 (7.6%) 44 (62.0%) 21 (29.6%) 6 (8.5%) 10 (55.6%) 6 (33.3%) 2 (11.1%)
Early perimenopausal 556 (52.8%) 342 (32.5%) 155 (14.7%) 252 (51.3%) 163 (33.2%) 76 (15.5%) 97 (52.7%) 58 (31.5%) 29 (15.8%)
Late perimenopausal 0 0 0 55 (35.5%) 49 (31.6%) 52 (32.9%) 29 (27.4%) 34 (32.1%) 43 (40.6%)
Postmenopausal 0 0 0 169 (43.0%) 106 (27.0%) 118 (30.0%) 142 (37.6%) 125 (33.1%) 111 (29.4%)
aInformation regarding VMS (vasomotor symptoms) was obtained annually from baseline to annual follow-up visit 8. Data are presented as n (%).
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In this longitudinal study, we found VMS to be positively
associated with NTX level among perimenopausal and post-
menopausal women. These associations were in large part
decreased by adjustment for serum FSH level but not by
adjustment for estradiol level. The pattern of results was similar
regardless of whether VMS frequency was characterized as any
versus none, as frequent versus not frequent, or as numbers of
days of VMS in the past 2 weeks.
Although the longitudinal associations of NTX and BMD have
not been established among women undergoing the meno-
pause transition, randomized, controlled trials of osteoporosis
pharmacotherapy in older women have related changes in NTX
level to changes in BMD. For example, a 30% decrease in NTX
level after 6 months of alendronate therapy corresponded to a
5.8% increase in lumbar BMD after 2.5 years of therapy.
(34) The
relations between NTX and BMD based on clinical trials cannot
be extrapolated directly to observational studies; however,
they suggest that the 9% difference in NTX between early
perimenopausal women with VMS and early perimenopausal
women without VMS may correspond to differences in BMD of
2%.
We are aware of only one previous study that has focused on
associations between VMS and urinary NTX level.
(22) That cross-
sectional study of premenopausal infertile women found serum
NTX to be higher among women reporting having night sweats
than among women reporting not having night sweats but
found no significant association between hot flashes and NTX
level.
(22) Because we did not find statistically significant
associations between VMS and NTX among the premenopausal
women, our results are in agreement with that prior study.
Moreover, our longitudinal study design may have allowed
enhanced sensitivity to detect associations of VMS and urinary
NTX.
These results may extend prior studies that reported lower
BMD among midlife women with VMS.
(8–11) Using data from
SWAN, we previously found that women with VMS had lower
BMD on average than women without VMS.
(9) Our findings
support the hypothesis that elevated NTX is one mechanism for
the inverse association of VMS with BMD among midlife women.
Our findings are biologically plausible. We have already
explored one possible biologic explanation for our findings in
this study: Serum FSH level appeared in part to explain the
associations between VMS and NTX level. In prior studies, serum
FSH concentration was associated with both higher NTX level
and higher frequency of VMS, and longitudinal losses of BMD
were more strongly associated with increases in FSH levels
rather than with changes in estradiol levels, albeit some of these
studies are similarly constrained by early-follicular-phase
sampling.
(24,35–39) Although others have found serum estradiol
level to be associated with BMD over the menopause
transition.
(40) adjustment for serum total estradiol did not
influence the associations between VMS and NTX in our study. In
a cross-sectional analysis, elevated bone turnover was apparent
among perimenopausal women despite circulating estradiol
levels that were similar to those of premenopausal women.
(39)
Priortothefinalmenstrualperiod,changesingonadalinhibins
may cause the trabecular bone loss that has been observed prior
to the onset of menopause.
(41) The rise in FSH during the
menopause transition is preceded by declining levels of inhibin
B, reflecting the fall in ovarian follicle levels, whereas estradiol
Table 4. Unadjusted Urinary NTX Level According to Presence of VMS by Menopausal Transition Stage
a
VMS any versus none
b VMS frequent versus not frequent
c
VMS
NTX level
d
p Value
e VMS
Ntx level
p Value
f Mean SD Mean SD
Premenopausal Overall (n¼2500) 33.51 15.45
None (n¼1739) 33.37 15.64 .48 Not frequent (n¼2323) 33.45 15.56 .44
Any (n¼761) 33.84 15.02 Frequent (n¼177) 34.38 13.97
Early perimenopausal Overall (n¼6066) 34.64 16.69
None (n¼3241) 33.92 15.76 <.001 Not frequent (n¼5218) 34.20 16.30 <.001
Any (n¼2825) 35.47 17.66 Frequent (n¼848) 37.35 18.70
Late perimenopausal Overall (n¼1040) 43.30 19.04
None (n¼324) 42.44 18.22 .33 Not frequent (n¼677) 42.22 18.40 .01
Any (n¼716) 43.69 19.40 Frequent (n¼363) 45.31 20.05
Postmenopausal Overall (n¼2529) 47.03 24.97
None (n¼995) 45.73 28.06 .04 Not frequent (n¼1793) 46.53 26.24 .09
Any (n¼1534) 47.88 22.72 Frequent (n¼736) 48.26 21.56
aValues of NTX (nM BCE/mM of creatinine) are averages over all years of follow-up within the given menopausal stage.
bWomen were consideredto have vasomotorsymptoms if they reported experiencing hotflashes or night sweats or bothin the past 2 weeks on annual
questionnaires.
c‘‘Frequent VMS’’ indicates VMS frequency 5 days in the past 2 weeks; ‘‘Not frequent VMS’’ indicates VMS frequency<5 days in the past 2 weeks.
dUnits of NTX are nM BCE/mM of creatinine.
ep Value for t test comparing mean NTX level of women with any VMS with the mean NTX level of women with no VMS.
fp Value for t test comparing mean NTX level of women with frequent VMS with the mean NTX level of women without frequent VMS.
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perimenopause, when FSH levels increase.
(42) FSH may have
direct effects on bone in part by enhancing receptor activator of
nuclear factor kB ligand (RANKL)–stimulated osteoclast devel-
opment and activity.
(43) Inhibins likely inhibit osteoblastogenesis
and osteoclastogenesis (reviewed in ref.
(44)). In a cross-sectional
study, FSH was significantly correlated with bone resorption
among perimenopausal women, but serum inhibin A predicted
bone resorption levels better in pre- and perimenopausal
women than did FSH or bioavailable estradiol.
(45)
Besides circulating FSH and inhibin levels, other possible
biologic mechanisms may underlie our findings. Although
associations of cortisol with increased urinary NTX among the
general population of midlife women have not been the focus of
previous studies, elevated cortisol levels are associated with
decreased BMD in certain disease states, such as major
depression and Cushing syndrome.
(46,47) Because cortisol levels
increase in the late perimenopausal stage,
(48) and because
cortisol levels may increase acutely after hot flashes,
(12,14,49)
increased cortisol levels associated with frequent VMS also may
leadtoelevatedNTXlevel.Althoughwewerenotabletotestthis
hypothesis directly owing to the lack of availability of data
regarding cortisol levels, we will explore possible mechanisms
underlying associations of VMS with NTX level.
In stratified analyses, no association between VMS and NTX
was evident among the subsample of participants whose serum
estradiol and FSH levels were drawn in the early follicular phase.
Thus the associations observed in the full sample were being
driven by the women whose blood samples were drawn outside
the early follicular phase, that is, in late perimenopausal
Table 5. Associations Between VMS and Urinary NTX Level in Multivariable-Adjusted Models
a
VMS any versus none:
basic model
VMS frequent versus not frequent:
basic model
b
Menopausal stage b coefficient
c SD p Value b coefficient
d SD p Value
Premenopausal 1.017 0.809 .17 0.741 1.436 .61
Early perimenopausal 1.944 0.486 <.0001 3.077 0.675 <.0001
Late perimenopausal 2.437 1.011 .03 3.625 1.069 <.001
Postmenopausal 1.259 0.769 .10 1.909 0.799 .02
VMS any versus none:
model with FSH
e
VMS frequent versus not frequent:
model with FSH
Menopausal stage b coefficient SD p Value b coefficient SD p Value
Premenopausal 0.802 0.805 .32 0.391 1.430 .78
Early perimenopausal 1.347 0.486 .006 2.024 0.676 .003
Late perimenopausal 1.071 1.107 .33 2.519 1.073 .02
Postmenopausal 0.546 0.769 .48 0.919 0.801 .25
VMS any versusnone:
model with estradiol
f
VMS frequent versus not frequent:
model with estradiol
Menopausal stage b coefficient SD p Value b coefficient SD p Value
Premenopausal 0.969 0.812 .23 0.701 1.442 .63
Early perimenopausal 1.784 0.489 <.001 2.827 0.679 <.0001
Late perimenopausal 2.022 1.113 .07 3.294 1.079 .002
Postmenopausal 1.307 0.774 .09 1.748 0.805 .06
VMS any versus none:
model with FSH and estradiol
g
VMS frequent versus not frequent:
model with FSH and estradiol
Menopausal stage b coefficient SD p Value b coefficient SD p Value
Premenopausal 0.787 0.805 .33 0.443 1.430 .76
Early perimenopausal 1.336 0.486 .006 1.022 0.676 .003
Late perimenopausal 1.042 1.107 .35 2.492 1.073 .02
Postmenopausal 0.557 0.769 .47 0.930 0.801 .25
aRepeated-measures models adjusted for age, smoking, BMI, race/ethnicity, calcium and vitamin D supplement intake, physical activity score (log-
transformed), alcohol intake (kcal/d, log-transformed), and study site.
b‘‘Frequent VMS’’ indicates VMS frequency 5 days in the past 2 weeks; ‘‘Not frequent VMS’’ indicates VMS frequency<5 days in the past 2 weeks.
cb coefficient represents the increment in urinary NTX (nM BCE/mM of creatinine) associated with reporting any VMS versus no VMS.
db coefficient represents the increment in urinary NTX (nM BCE/mM of creatinine) comparing frequent VMS with not frequent VMS.
eIncludes variables of basic model, follicle-stimulating hormone level (FSH, IU/L) and menstrual cycle phase (follicular versus not follicular or unknown
phase).
fRepeated-measures models adjusted for variables of the basic model, serum estradiol concentration (pg/mL), and menstrual cycle phase.
gRepeated-measures models adjusted for variables of the basic model, serum FSH level, serum estradiol concentration, and menstrual cycle phase.
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tions between VMS and NTX among women who had
early-follicular-phase phlebotomy may be explained by the
low variation in VMS and NTX among women with early-
follicular-phase estradiol and FSH sampling (who were more
likely to be pre- or early perimenopausal women) compared
with women whose blood samples were not drawn in the
early follicular phase (who were more likely to be late peri- or
postmenopausal). In this study, it is not possible to completely
disaggregate menopausal stage per se from timing (early
follicular phase versus not early follicular phase) of blood
sampling.
Finally, another explanation for the associations of VMS with
NTX level may be that within a given menstrually based
menopause stage, VMS are an indication of more advanced
ovarian aging (ie, that when added to menstrually based
menopause transition stage, VMS further refine the estimation of
ovarian aging). We would expect that a more advanced
menopausal stage would be associated with higher bone
turnover.
A previous SWAN analysis demonstrated that BMD changed
little during pre- or early perimenopause but declined
substantially in the late perimenopausal period.
(50) The rate of
BMD loss in late perimenopause was similar to that in the first
two postmenopausal years.
(50) A time lag may occur in the BMD
response to increasing NTX levels so that the early perimeno-
pausal rise in NTX would be apparent before the late
perimenopausal drop in BMD noted in the prior study.
Strengths of our study include its community-based multi-
ethnic recruitment strategy, large sample size, and longitudinal
design. Our study had potential limitations. First, our method of
VMS assessment, which has been used frequently in longitudinal
studies, theoretically could have yielded an underestimate of
true VMS frequency, that is, would not have assessed VMS
frequency other than in the past 2 weeks. Thus our results may
have been attenuated as a result of this type of misclassification.
Also, we did not include measures of daily frequency and
bothersomeness of hot flashes because these were not obtained
in SWAN until visit 7; thus future SWAN analyses with more
longitudinal data should examine the relation of these measures
to bone turnover. Second, our annual questionnaire assessments
of calcium intake, vitamin D intake, and physical activity levels
may not have been as reliable as those which would have been
affordedbyprospectivelycollectedfoodandsupplementdiaries,
which might have resulted in a conservative bias (toward the
null).
In conclusion, among early perimenopausal and late perime-
nopausal women, we found that women with VMS had
significantly higher NTX levels than women without VMS. Prior
to the final menstrual period, VMS may be a marker for elevated
bone turnover. It is not definitely established whether women
with VMS prior to the final menstrual period are at higher risk of
osteoporotic fracture. However, high bone turnover is associated
with lower BMD, faster bone loss, and poor bone microarch-
itecture both in the trabecular compartment (trabecular
perforations, loss of trabeculae, poor trabecular connectivity)
and in the cortical compartment (cortical thinning, increased
porosity).
(51–53)
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